On the other hand, the use of a CXCR4 antagonist induced inhibition of tumor cell infiltration, followed by decrease in tracer uptake, indicating that ([18F]FB-IL-2) may guide cancer immunotherapy. This evidence concerns the gene IL2 and neoplasm.